Seal Rock Therapeutics, Inc. focuses on the exploration and creation of small compound blockers of ASK1 (apoptosis signal-regulating kinase 1), a protein that controls cell death, inflammation, and scarring. The company is currently directing its attention to liver-related conditions such as NASH (non-alcoholic steatohepatitis), a disorder originating from fatty liver disease, marked by liver swelling and cell harm resulting in liver scarring. There are also further prospects for using ASK1 blockers in heart, immune system, and neurodegenerative conditions.
Seal Rock Therapeutics
Headquarters
United States of America